This study explores how inflammation and cholesterol levels predict cardiovascular events among 13,970 statin-intolerant patients in the CLEAR Outcomes trial. Findings suggest residual inflammatory risk may be a stronger predictor than residual cholesterol risk for future events. The research analyz

0 views • 17 slides

Cardiovascular disease is a growing concern in individuals living with HIV, despite advancements in treatment. The REPRIEVE Trial sheds light on the importance of assessing cardiovascular risk and implementing primary prevention measures in this population. Dr. Grinspoon's financial disclosures and

0 views • 35 slides

The CLEAR Outcomes Trial investigated the effects of bempedoic acid, an ATP citrate lyase inhibitor, on cardiovascular outcomes in primary prevention patients. Results showed a reduction in cardiovascular events with bempedoic acid, particularly in patients intolerant to statins. Baseline characteri

0 views • 13 slides

Major lipids like cholesterol and triglycerides play essential roles in the body, but their excess can lead to hyperlipidemia and related conditions. This overview covers the biosynthesis of cholesterol, triglycerides, and the transport of lipids in the bloodstream, discussing the importance of lipo

1 views • 30 slides

This presentation covers drugs for hyperlipidemia, including bile acid sequestrants, cholesterol absorption inhibitors, statins, fibrates, and relevant drug interactions. It details the actions, adverse effects, contraindications, and notable considerations for each drug class. The included multiple

0 views • 6 slides

Statin intolerance is the inability to tolerate at least two statins, with symptoms like muscle aches. Despite the benefits of statins in reducing cardiovascular risk, some patients experience side effects leading to intolerance. Understanding the definition, prevalence, and management of statin int

0 views • 43 slides